SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased securities of Sarepta Therapeutics, Inc. during the specified Class Period from June 22, 2023, to June 24, 2025, due to alleged misleading statements regarding the safety and efficacy of their gene therapy product, ELEVIDYS [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Sarepta Therapeutics made false and misleading statements about ELEVIDYS, a gene therapy for Duchenne muscular dystrophy, which posed significant safety risks and failed to detect severe side effects [5]. - The lawsuit alleges that the adverse events from ELEVIDYS treatment would lead to a halt in recruitment and dosing in trials, attract regulatory scrutiny, and increase risks around the therapy's approvals [5]. - Investors are encouraged to join the class action without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by August 25, 2025, to represent the class in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].